Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gabapentin
Drug ID BADD_D00981
Description Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993.[L8717] It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to treat neuropathic pain.[A14097,A186179] Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.[A186143,A185981,L8717]. It is structurally and functionally related to another GABA derivative, [pregabalin].
Indications and Usage In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older.[L8717] In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in patients 6 years of age and older and as monotherapy in patients 12 years of age and older. It is also used in adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.[L8732]
Marketing Status approved; investigational
ATC Code N02BF01
DrugBank ID DB00996
KEGG ID D00332
MeSH ID D000077206
PubChem ID 3446
TTD Drug ID D0J0ZS
NDC Product Code 72789-055; 72888-132; 76420-235; 80425-0031; 80425-0097; 80425-0182; 82009-071; 52133-0025; 62331-031; 64220-211; 69617-002; 71574-121; 71901-609; 16714-332; 25000-103; 42385-974; 43602-466; 49483-607; 51407-047; 0228-2636; 52427-815; 53002-3423; 55289-959; 55700-584; 60687-591; 61919-640; 62756-202; 63187-006; 63187-010; 63187-810; 63629-7666; 63629-8490; 63739-560; 63739-591; 67877-429; 68001-412; 68071-5193; 68382-205; 68788-7822; 68788-7839; 68788-8176; 70010-926; 70518-0810; 70518-1760; 71093-120; 71205-317; 71205-485; 71205-619; 71205-638; 71335-0351; 71335-1007; 71335-1132; 71335-1200; 71335-1269; 71335-1496; 71610-044; 71610-621; 72789-127; 76282-706; 80425-0286; 83301-0002; 45963-556; 57884-0010; 65977-0054; 0071-0803; 16714-504; 42385-972; 43602-470; 50383-311; 50383-351; 51224-219; 51407-048; 51407-049; 52427-850; 53002-1538; 55700-780; 55700-950; 60687-518; 60760-088; 60760-814; 61919-387; 62756-139; 63187-372; 63187-392; 63629-8485; 63629-8487; 63739-236; 65162-102; 65862-524; 67877-428; 68071-3445; 69367-344; 70010-927; 70518-3330; 71093-122; 71205-373; 71205-533; 71335-0073; 71335-1287; 71335-2004; 71610-057; 71610-060; 71610-088; 71610-166; 71610-410; 71610-426; 0615-8132; 0615-8233; 0615-8340; 76420-234; 80425-0128; 83301-0001; 42765-018; 65862-523; 16714-663; 17856-0698; 42806-509; 42806-510; 43353-075; 43353-081; 43353-864; 43602-467; 43602-469; 45865-122; 49483-606; 50090-0949; 50090-3915; 50228-178; 50268-325; 51224-019; 55154-8193; 55154-8195; 59088-725; 59762-5050; 60687-602; 62756-137; 62756-138; 63187-909; 65862-200; 68071-2308; 68071-2600; 68071-2883; 68071-2907; 68462-126; 68788-7838; 68788-8475; 69097-811; 69097-814; 69367-131; 69367-133; 70518-1469; 70518-1544; 70518-2323; 70518-2912; 70518-2970; 70518-3755; 71205-932; 71335-1012; 71335-1655; 71610-198; 72189-394; 53746-101; 55154-3366; 59762-4135; 60760-605; 61919-350; 61919-417; 63187-057; 63629-8488; 63739-902; 64380-867; 68788-7024; 68788-7774; 68788-8468; 68788-8476; 70010-109; 70518-2911; 70518-3708; 71205-766; 71335-0254; 71335-0820; 71335-0993; 71335-1198; 71610-072; 72162-1813; 72189-419; 76420-047; 80425-0158; 82982-049; 82982-067; 17337-0415; 45963-557; 49452-3241; 65862-198; 66651-901; 0071-0401; 68554-0128; 82393-212; 16714-661; 31722-167; 45963-555; 49483-605; 50090-5961; 50228-180; 53002-4423; 55154-7993; 61919-982; 63187-148; 63187-983; 63739-903; 65841-705; 65841-706; 67296-1536; 68071-4978; 69367-134; 69367-135; 69367-346; 70010-118; 70518-3140; 70934-284; 70934-933; 71205-160; 71205-514; 71205-671; 71205-808; 71205-931; 71335-1018; 71335-1991; 71610-090; 71610-188; 72189-392; 0615-8342; 72888-104; 76282-405; 80425-0032; 80425-0033; 80425-0149; 0904-6665; 0228-2637; 65862-199; 68981-009; 71052-176; 0071-2012; 16571-868; 31722-149; 42385-973; 43602-471; 45865-405; 45865-498; 45865-549; 50090-3200; 50090-4445; 50090-4893; 50228-177; 50436-0223; 52427-804; 52427-890; 55700-949; 60760-066; 60760-740; 61919-660; 62207-927; 63187-056; 63187-149; 63187-248; 63629-3063; 63629-8489; 63629-8491; 63629-8492; 64380-868; 68071-2206; 68788-7848; 68788-8199; 69097-813; 69097-815; 69844-055; 69844-056; 70010-228; 70518-2493; 70518-3103; 70518-3329; 70934-950; 70934-953; 71093-111; 71093-162; 71335-1199; 71335-1453; 71335-1997; 71335-2053; 71610-135; 71610-667; 72189-092; 72189-313; 72189-384; 72888-131; 76282-323; 80425-0035; 80425-0082; 80425-0150; 82009-072
UNII 6CW7F3G59X
Synonyms Gabapentin | 1-(Aminomethyl)cyclohexaneacetic Acid | Neurontin | Gabapentin Hexal | Convalis | Gabapentin-Ratiopharm | Gabapentin Ratiopharm | Novo-Gabapentin | Novo Gabapentin | NovoGabapentin | PMS-Gabapentin | Apo-Gabapentin | Apo Gabapentin | ApoGabapentin | Gabapentin Stada
Chemical Information
Molecular Formula C9H17NO2
CAS Registry Number 60142-96-3
SMILES C1CCC(CC1)(CC(=O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.0010.000073%-
Altered visual depth perception06.02.04.006; 17.17.01.0020.000053%-
Type IV hypersensitivity reaction10.01.03.0220.000037%-
Vascular rupture12.01.11.006; 24.03.02.0230.000016%-
Growth retardation05.03.02.007; 14.03.02.031; 15.03.05.0160.000021%
Nodule08.03.05.002---
Affect lability19.04.01.001---
Skin burning sensation17.02.06.009; 23.03.03.0210.000097%-
Dysphemia17.02.08.010; 19.19.03.0050.000118%-
Haemorrhage24.07.01.002---
Postmenopausal haemorrhage21.02.01.002; 24.07.03.0020.000016%-
Food craving14.03.01.009; 19.09.01.0100.000124%-
Gaze palsy06.05.02.014; 17.02.05.0440.000037%-
Daydreaming19.21.02.0050.000023%-
Hypoaesthesia oral07.05.05.003; 17.02.06.0210.000166%-
Paraesthesia oral07.05.05.035; 17.02.06.0080.000054%-
Bipolar disorder19.16.01.0030.000026%-
Cognitive disorder17.03.03.003; 19.21.02.0010.000571%
Major depression19.15.01.0030.000057%-
Toxic skin eruption10.01.01.008; 12.03.01.073; 23.03.05.0030.000057%-
Metabolic disorder14.11.01.0010.000016%-
Neutrophilic dermatosis01.02.01.013; 23.03.03.0590.000016%-
Ocular icterus01.06.04.007; 06.08.03.009; 09.01.01.0070.000033%-
Dysgraphia17.02.03.0060.000026%-
Vasodilation procedure25.03.01.001---
Muscle relaxant therapy25.16.01.001---
Restless legs syndrome15.05.03.012; 17.02.07.0080.000122%-
Disturbance in sexual arousal19.08.04.003---
Cerebral vasoconstriction17.08.02.012; 24.04.06.0250.000016%-
Infrequent bowel movements07.02.02.0110.000016%-
The 25th Page    First    Pre   25 26 27 28 29    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene